The MDA grant will be used to evaluate the effect of the pharmacological chaperone AT2220 on immunogenicity related to the ERT alglucosidase alfa, the approved treatment for Pompe disease.
Amicus will evaluate the ability of AT2220 to mitigate ERT-specific immunogenicity from blood samples obtained in the Phase 2 drug-drug interaction study of AT2220.
Amicus chairman and CEO John Crowley said the MDA grant validates their early preclinical work and supports their ongoing evaluation of AT2220 on ERT-related immunogenicity.